The link between cholesterol and Alzheimer's disease

World Journal of Biological Psychiatry

Volumn 6, Issue 2, 2005, Pages 85-97

  Sjögren, Magnus ^a   Blennow, Kaj ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

amyloid; secretase; Amyloid precursor protein; Cholesterol; Statins

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA SECRETASE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER; DIURETIC AGENT; GAMMA SECRETASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYL BETA CYCLODEXTRIN; MEVINOLIN; OLIGOMER; PRAVASTATIN; PRESENILIN 1; PRESENILIN 2; ROSUVASTATIN; SIMVASTATIN;

ALLELE; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; DRUG PENETRATION; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GENETIC RISK; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PLEIOTROPY; PROTEIN DEGRADATION; PROTEIN METABOLISM; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SENILE PLAQUE;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; CHOLESTEROL; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; RISK FACTORS;

EID: 21244494408     PISSN: 15622975     EISSN: None     Source Type: Journal    
DOI: 10.1080/15622970510029795     Document Type: Review

References (150)

1. S-study-group. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383-1389.
2. Aguero-Torres H, Winblad B. 2000. Alzheimer's disease and vascular dementia. Some points of confluence. Ann NY Acad Sci 903:547-552.
3. Alaupovic P. 1982. The role of apolipoproteins in lipid transport processes. Ric Clin Lab 12(1):3-21.
4. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI. 1998. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273(21):12817-12826.
5. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM. 1997. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17(3):263-264.
6. Beffert U, Aumont N, Dea D, Lussier Cacan S, Davignon J, Poirier J. 1998. Beta-amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons. J Neurochem 70(4):1458-1466.
7. Beffert U, Aumont N, Dea D, Lussier-Cacan S, Davignon J, Poirier J. 1999. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Brain Res Mol Brain Res 68(1-2):181-185.
8. Beffert U, Poirier J. 1996. Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Ann NY Acad Sci 777:166-174.
9. Beffert U, Poirier J. 1998. ApoE associated with lipid has a reduced capacity to inhibit beta-amyloid fibril formation. Neuroreport 9(14):3321-3323.
10. Blennow K, Skoog I. 1999. Genetic testing for Alzheimer's disease: How close is reality? Curr Opin Psychiatry 12:487-493.
11. Blumenthal RS. 2000. Statins: Effective antiatherosclerotic therapy. Am Heart J 139(4):577-583.
12. Bodovitz S, Klein WL. 1996. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271(8):4436-4440.
13. Bonn V, Cheung RC, Chen B, Taghibiglou C, Van Iderstine SC, Adeli K. 2002. Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis 163(1):59-68.
14. Borroni B, Archetti S, Agosti C, Akkawi N, Brambilla C, Caimi L, Caltagirone C, Di Luca M, Padovani A. 2004. Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: From risk factors to disease modulators. Neurobiol Aging 25(6):747-751.
15. Boyles JK, Zoellner CD, Anderson LJ, Kosik LM, Pitas RE, Weisgraber KH, Hui DY, Mahley RW, Gebicke-Haerter PJ, Ignatius MJ, et al. 1989. A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest 83(3):1015-1031.
16. Breteler MM, Claus JJ, Grobbee DE, Hofman A. 1994. Cardiovascular disease and distribution of cognitive function in elderly people: The Rotterdam Study. Br Med J 308(6944):1604-1608.
17. Brookmeyer R, Gray S, Kawas C. 1998. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88(9):1337-1342.
18. Brown BG, Zhao XQ, Sacco DE, Albers JJ. 1993. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 87(6):1781-1791.
19. Bush AI. 2002. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 23(6):1031-1038.
20. Bush AI. 2003. Copper, zinc, and the metallobiology of Alzheimer disease. Alzheimer Dis Assoc Disord 17(3):147-150.
21. Bush AI, Pettingell WH Jr, Paradis MD, Tanzi RE. 1994a. Modulation of A beta adhesiveness and secretase site cleavage by zinc. J Biol Chem 269(16):12152-12158.
22. Bush AI, Pettingell WH, Multhaup G, Paradis MD, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. 1994b. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265(5177):1464-1467.
23. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Kraft GA, Klein WL. 2003. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42(44):12749-12760.
24. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261(5123):921-923.
25. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P. 2004. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet 363(9427):2105-2115.
26. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. 2001. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103(7):926-933.
27. Crowther RA, Wischik CM. 1985. Image reconstruction of the Alzheimer paired helical filament. EMBO J 4(13B):3661-3665.
28. Cucchiara B, Kasner SE. 2001. Use of statins in CNS disorders. J Neurol Sci 187(1-2):81-89.
29. Davignon J, Laaksonen R. 1999. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 10(6):543-59.
30. de la Torre JC. 2002. Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 33 (4): 1152-1162.
31. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. 1998. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391(6665):387-390.
32. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98(15):8850-8855.
33. Eastwood R, Amaducci L, Brayne C, Broe T, Burns A, Copeland J, Dickens B, Goate A, Hachinski V, Henderson S, Jolles J, Ritchie MJK, Roses A, Rossor M, Schellenberg G, Skoog I, Storandt M, Tallis R, Whitehouse P, Clark S, Evans I, Horton R, Sharp D. 1996. The challenge of the dementias. Lancet 347:1303-1307.
34. Eckert GP, Kirsch C, Mueller WE. 2001. Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice. Neuroreport 12(5):883-887.
35. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. 2003. Amyloidogenic processing of the Alzheimer {beta}-amyloid precursor protein depends on lipid rafts. J Cell Biol 160(1):113-123.
36. Eto M, Watanabe K, Chonan N, Ishii K. 1988. Familial hypercholesterolemia and apolipoprotein E4. Atherosclerosis 72(2-3):123-128.
37. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hermerici M, Beyreuther K, Hartmann T. 2001. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98(10):5856-5861.
38. Ferrari A, Hoerndli F, Baechi T, Nitsch RM, Gotz J. 2003. beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem 278(41):40162-40168.
39. Finefrock AE, Bush AI, Doraiswamy PM. 2003. Current status of metals as therapeutic targets in Alzheimer's disease. J Am Geriatr Soc 51(8):1143-1148.
40. Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. 1999. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 10(8):1699-1705.
41. Frederickson CJ. 1989. Neurobiology of zinc and zinc-containing neurons. Int Rev Neurobiol 31:145-238.
42. Friedhoff LT, Cullen EI, Geoghagen NS, Buxbaum JD. 2001. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int J Neuropsychopharmacol 4(2):127-130.
43. Furman C, Copin C, Kandoussi M, Davidson R, Moreau M, McTaggiart F, Chapman MJ, Fruchart JC, Rouis M. 2004. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: Potential relevance to atherosclerotic plaque stability. Atherosclerosis 174(1):93-98.
44. Galbete JL, Martin TR, Peressini E, Modena P, Bianchi R, Forloni G. 2000. Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem J 348(Pt 2):307-313.
45. Gatz M, Pedersen NL, Berg S, Johansson B, Johansson K, Mortimer JA, Posner SF, Viitanen M, Winblad B, Ahlbom A. 1997. Heritability for Alzheimer's disease: The study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci 52(2):M117-125.
46. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA. 1998. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med 4(7):827-831.
47. Goedert M. 1993. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 16(11):460-465.
48. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. 1988. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 85(11):4051-4055.
49. Gotz J, Chen F, van Dorpe J, Nitsch RM. 2001. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 293(5534):1491-1495.
50. Graves AB, van Duijn CM, Chandra V, Fratiglioni L, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA, Rocca WA, et al. 1991. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: A collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 20(Suppl 2):S48-57.
51. Haass C, Selkoe DJ. 1993. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 75(6):1039-1042.
52. Hardy J, Allsop D. 1991. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12:383-388.
53. Hartmann H, Eckert A, Muller WE. 1994. Apolipoprotein E and cholesterol affect neuronal calcium signalling: The possible relationship to beta-amyloid neurotoxicity. Biochem Biophys Res Commun 200(3):1185-1192.
54. Heber D, Koziol BJ, Henson LC. 1987. Low density lipoprotein receptor regulation and the cellular basis of atherosclerosis: Implications for nutritional and pharmacologic treatment of hypercholesterolemia. Am J Cardiol 60(12):4-8G.
55. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. 1997. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. J Am Med Assoc 278(4):313-321.
56. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. 1998. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101(12):2711-2719.
57. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. 2000. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 87(7):616-622.
58. Hofman A, Ott A, Breteler MM, Bots MI, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE. 1997. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349(9046):151-154.
59. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. 2000. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97(6):2892-2897.
60. Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD, Maeda N, Siman R, Greenberg BD, Scott RW, Flood DG. 1998. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem 273(26):16576-16582.
61. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. 2000. Statins and the risk of dementia. Lancet 356(9242):1627-1631.
62. Jula A, Marniemi J, Huupponen R, Virtanen A, Pastas M, Ronnemaa T. 2002. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: A randomized controlled trial. J Am Med Assoc 287(5):598-605.
63. Kawahara M, Kuroda Y. 2001. Intracellular calcium changes in neuronal cells induced by Alzheimer's beta-amyloid protein are blocked by estradiol and cholesterol. Cell Mol Neurobiol 21(1):1-13.
64. Kidd M. 1963. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 197:192-193.
65. Kilsdonk EP, Yancey PG, Stoudt GW, Bangerter FW, Johnson WJ, Phillips MC, Rothblat GH. 1995. Cellular cholesterol efflux mediated by cyclodextrins. J Biol Chem 270(29):17250-17256.
66. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. 2001. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. Br Med J 322(7300):1447-1451.
67. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. 2001. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci USA 98(10):5815-5820.
68. Kolsch H, Lutjohann D, Ludwig M, Schulte A, Ptok U, Jessen F, von Bergmann K, Rao ME, Maier W, Heun R. 2002. Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol Psychiatry 7(8):899-902.
69. Kurochkin IV, Goto S. 1994. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345(1):33-37.
70. Kwak BR, Veillard N, Pelli G, Mulhaupt F, James RW, Chanson M, Mach F. 2003. Reduced connexin3 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation 107(7):1033-1039.
71. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M. 2000. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31(10):2442-2449.
72. Lennernas H, Fager G. 1997. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 32(5):403-425.
73. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al. 1995. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269(5226):973-977.
74. Li YM, Lai MT, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK, Shi XP, Yin KC, Sharer JA, Gardell SJ. 2000. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci USA 97(11):6138-6143.
75. Locatelli S, Lutjohann D, Schmidt HH, Otto C, Beisiegel U, von Bergmann K. 2002. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: Evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 59(2):213-216.
76. Lomnitski L, Kohen R, Chen Y, Shohami E, Trembovler V, Vogel T, Michaelson DM. 1997. Reduced levels of antioxidants in brains of apolipoprotein E-defcient mice following closed head injury. Pharmacol Biochem Behav 56(4):669-673.
77. Lutjohann D, Papassotiropoulos A, Bjorkhem I, Locatelli S, Bagli M, Oehring RD, Schlegel U, Jessen F, Rao ML, von Bergmann K, Heun R. 2000. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 41(2):195-198.
78. Maron DJ, Fazio S, Linton MF. 2000. Current perspectives on statins. Circulation 101(2):207-213.
79. Michikawa M, Fan QW, Isobe I, Yanagisawa K. 2000. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 74(3):1008-1016.
80. Nawawi H, Osman NS, Yusoff K, Khalid BA. 2003. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm Metab Res 35(8):479-485.
81. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A. 1998. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17(1):14-20.
82. Octave JN. 1995. The amyloid peptide precursor in Alzheimer's disease. Acta Neurol Belg 95(4):197-209.
83. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, Renaud S, Breteler MB. 1997. Wine consumption and dementia in the elderly: A prospective community study in the Bordeaux area. Rev Neurol (Paris) 153(3):185-192.
84. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM.. 1996. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39(11):1392-1397.
85. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. 1999. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53(9):1937-1942.
86. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, Ptok U, Bjorkhem I, von Bergmann K, Heun R. 2002. 24S-Hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 36(1):27-32.
87. Papassotiropoulos A, Streffer JR, Tsolaki M, Schmid S, Thal D, Nicosia F, Iakovidou V, Maddalena A, Lutjohann D, Ghebremedhin E, Hegi T, Pasch T, Traxler M, Bruhl A, Benussi L, Binetti G, Braak H, Nitsch RM, Hock C. 2003. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 60(1):29-35.
88. Poirier J, Panisset M. 2002. Apolipoprotein E: A Novel therapeutic target for the treatment of Alzheimer's disease. Adv Behav Biol 1:36-42.
89. Prokop S, Shirotani K, Edbauer D, Haass C, Steiner H. 2004. Requirement of PEN-2 for stabilization of the presenilin N-/C-terminal fragment heterodimer within the gamma-secretase complex. J Biol Chem 279(22):23255-23261.
90. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM. 2001. Acyl-coenzyme A:cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 3(10):905-912.
91. Racchi M, Baetta R, Salvietti N, Ianna P, Franceschini G, Paoletti R, Fumagalli R, Govoni S, Trabucchi M, Soma M. 1997. Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem J 322(Pt 3):893-898.
92. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA. 2000. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7(4):321-331.
93. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE. 2001. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8(5):890-899.
94. Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, Sjogren M, Wallin A, Xilinas M, Gotffries CG. 2001. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 12(6):408-414.
95. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. 2001. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 98(6):3334-3339.
96. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. 2003. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 60(12):1685-1691.
97. Rocchi A, Pellegrini S, Siciliano G, Murri L. 2003. Causative and susceptibility genes for Alzheimer's disease: A review. Brain Res Bull 61(1):1-24.
98. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I.. 2002. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59(2):223-7.
99. Rosenberg RN. 2000. The molecular and genetic basis of AD: The end of the beginning: The 2000 Wartenberg Lecture. Neurology 54(11):2045-2054.
100. Rudel LL, Lee RG, Cockman TL. 2001. Acyl coenzyme A: Cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. Curr Opin Lipidol 12(2):121-127.
101. Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, Hartmann T. 2002. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci 22(5):1679-1689.
102. Sabo SL, Ikin AF, Buxbaum JD, Greengard P. 2001. The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement. J Cell Biol 153(7):1403-1414.
103. Sano M, Ernesto C, Thomas R, Klanber M, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman C, Pfeiffer E, Schneider L, Thal L. 1997. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. New Engl J Med 336:1216-1222.
104. Schneider WJ. 1990. Familial hypercholesterolemia: Dissection of a receptor disease. Z Kardiol 79(Suppl 3):3-7.
105. Schonknecht P, Lutjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, Beyreuther K, Schroder J. 2002.
106. Scott HD, Laake K. 2001 Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev(4):CD003160.
107. Selkoe DJ. 2000. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 924:17-25.
108. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. 1995. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375(6534):754-760.
109. Simons K, Ikonen E. 2000. How cells handle cholesterol. Science 290(5497):1721-1726.
110. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. 1998. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95(11):6460-6464.
111. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans I, Wormstall H, Hartmann T, Schulz JB. 2002. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52(3):346-350.
112. Sing CF, Davignon J. 1985. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 37(2):268-285.
113. Sjogren M, Gustafsson K, Syversen S, Olsson A, Edman A, Davidsson P, Wallin A, Blennow K. 2003. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved APP. Dementia Geriatr Cogn Dis 16(1):25-30.
114. Skoog I. 1997. Elevated blood pressure and Alzheimer's disease. Hosp Pract(Off Ed) 32(4):13-14, 16, 21.
115. Skoog I. 1999. The interaction between vascular disorders and Alzheimer's disease. In: Wisniewski H, editor. Alzheimer's disease and related disorders: Etiology, Pathogenesis and therapeutics. Chichester: John Wiley & Sons Ltd. p 523-530.
116. Skoog I, Gustafson D. 1999. HRT and dementia. J Epidemiol Biostat 4(3) :227-251; discussion 252.
117. Skoog I, Lernfelt B, Landahl S. 1996a. High blood pressure and dementia. Lancet 348:65-66.
118. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A. 1996b. 15-year longitudinal study of blood pressure and dementia. Lancet 347(9009):1141-1145.
119. Skoog I, Kalaria RN, Breteler MM. 1999. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 13(Suppl 3):S106-114.
120. Small BJ, Graves AB, McEvoy CL, Crawford FC, Mullan M, Mortimer JA. 2000. Is APOE-epsilon4 a risk factor for cognitive impairment in normal aging? Neurology 54(11):2082-2088.
121. Small DH, Nurcombe V, Reed G, Clarris H, Moir R, Beyreuther K, Masters CL. 1994. A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J Neurosci 14(4):2117-2127.
122. Smith GE, Bohac DL, Waring SC, Kokmen E, Tangalos EG, Ivnik RJ, Petersen RC. 1998. Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects. Neurology 50(2):355-362.
123. Sparks DL. 1997. Coronary artery disease, hypertension, ApoE, and cholesterol: A link to Alzheimer's disease? Ann NY Acad Sci 826:128-146.
124. Sparks DL, Scheff SW, Hunsaker JC 3rd, Liu H, Landers T, Gross DR. 1994. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126(1):88-94.
125. Sparks DL, Martin TA, Gross DR, Hunsaker JC 3rd. 2000. Link between heart disease, cholesterol, and Alzheimer's disease: A review. Microsc Res Tech 50(4):287-290.
126. Sparks L. 2004. Benefit of atorvastatin in the treatment of Alzheimer's disease. Springfield Symposium 2004, Montreal.
127. Staehelin HB, Perrig-Chiello P, Mitrache C, Miserez AR, Perrig WJ. 1999. Apolipoprotein E genotypes and cognitive functions in healthy elderly persons. Acta Neurol Scand 100(1):53-60.
128. Stamler J, Shekelle R. 1988. Dietary cholesterol and human coronary heart disease. The epidemiologic evidence. Arch Pathol Lab Med 112(10):1032-1040.
129. Strittmatter WJ, Roses AD. 1995. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 92(11):4725-4727.
130. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y. 1994. High tissue content of soluble beta1-40 is linked to cerebral amyloid angiopathy. Am J Pathol 145:452-460.
131. Svennerholm L, Gottfries CG. 1994. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form(type I) and demyelination in late-onset form(type II). J Neurochem 62(3):1039-1047.
132. Svensson AL, Nordberg A. 1998. Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells. Neuroreport 9(7):1519-1522.
133. Takemoto M, Liao JK. 2001. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21(11):1712-1719.
134. Tanaka K, Honda M, Takabatake T. 2004. Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation. Clin Exp Pharmacol Physiol 31(5-6):360-364.
135. Tanzi RE, Kovacs DM, Kim TW, Moir RD, Guenette SY, Wasco W. 1996. The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis 3(3):159-168.
136. Tomlinson B, Henderson G. 1976. Some quantitative cerebral findings in normal and demented old people. In: Terry RD, editor. Neurobiology of aging. New York: Raven Press.
137. Tomlinson BE, Corsellis JAN. 1984. Ageing and the dementias. In: Hume Adams J, Corsellis JAN, Duchen LW, editors. Greenfield's neuropathology. London: Edward Arnold. p 951-1025.
138. Tun H, Marlow L, Pinnix I, Kinsey R, Sambamurti K. 2002. Lipid rafts play an important role in A beta biogenesis by regulating the beta-secretase pathway. J Mol Neurosci 19(1-2):31-35.
139. Wada S, Morishima-Kawashima M, Qi Y, Misono H, Shimada Y, Ohno-Iwashita Y, Ihara Y. 2003. Gamma-secretase activity is present in rafts but is not cholesterol-dependent. Biochemistry 42(47):13977-13986.
140. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. 2000. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39(35):10831-10839.
141. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G. 2002. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22(2):300-305.
142. Vaughan CJ, Murphy MB, Buckley BM. 1996. Statins do more than just lower cholesterol. Lancet 348(9034):1079-1082.
143. Vega GL, Weiner MF, Lipton AM, Von Bergmann K, Lutjohann D, Moore C, Svetlik D. 2003. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 60(4):510-515.
144. Williams JK, Sukhova GK, Herrington DM, Libby P. 1998. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 31(3):684-691.
145. Wischik CM, Novak M, Thogersen HC, Edwards PC, Runswick MJ, Jakes R, Walker JE, Milstein C, Roth M, Klug A. 1988. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA 85(12):4506-4510.
146. Wisniewski K, George A, Moretz R, Wisniewski H. 1979. Alzheimer neurofibrillary tangles in diseases other than senile and presenile dementia. Ann Neurol 5:288-294.
147. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. 2000. Decreased prevalence of alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57(10):1439-1443.
148. Wu CW, Liao PC, Lin C, Kuo CJ, Chen ST, Chen H, Kuo YM. 2003. Brain region-dependent increases in beta-amyloid and apolipoprotein E levels in hypercholesterolemic rabbits. J Neural Transm 110(6):641-649.
149. Yaffe K, Barrett-Connor E, Lin F, Grady D. 2002. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59(3):378-384.
150. Yu G, Chen F, Levesque G, Nishimura M, Zhang DM, Levesque L, Rogaeva E, Xu D, Liang Y, Duthie M, St George-Hyslop PH, Fraser PE. 1998. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin. J Biol Chem 273(26):16470-16475.